全文获取类型
收费全文 | 359405篇 |
免费 | 287652篇 |
国内免费 | 43165篇 |
专业分类
耳鼻咽喉 | 3247篇 |
儿科学 | 5591篇 |
妇产科学 | 3913篇 |
基础医学 | 102251篇 |
口腔科学 | 4404篇 |
临床医学 | 73255篇 |
内科学 | 110958篇 |
皮肤病学 | 6042篇 |
神经病学 | 27392篇 |
特种医学 | 13035篇 |
外国民族医学 | 71篇 |
外科学 | 53985篇 |
综合类 | 70842篇 |
现状与发展 | 32篇 |
一般理论 | 20篇 |
预防医学 | 48324篇 |
眼科学 | 20631篇 |
药学 | 69884篇 |
126篇 | |
中国医学 | 52144篇 |
肿瘤学 | 24075篇 |
出版年
2022年 | 6882篇 |
2021年 | 9075篇 |
2020年 | 10049篇 |
2019年 | 16780篇 |
2018年 | 17464篇 |
2017年 | 17678篇 |
2016年 | 16213篇 |
2015年 | 17711篇 |
2014年 | 18759篇 |
2013年 | 18170篇 |
2012年 | 20829篇 |
2011年 | 23417篇 |
2010年 | 22300篇 |
2009年 | 28855篇 |
2008年 | 18087篇 |
2007年 | 14952篇 |
2006年 | 14217篇 |
2005年 | 13837篇 |
2004年 | 14081篇 |
2003年 | 13149篇 |
2002年 | 12883篇 |
2001年 | 14373篇 |
2000年 | 10006篇 |
1999年 | 15227篇 |
1998年 | 15432篇 |
1997年 | 15419篇 |
1996年 | 16058篇 |
1995年 | 16099篇 |
1994年 | 15697篇 |
1993年 | 14076篇 |
1992年 | 13663篇 |
1991年 | 12886篇 |
1990年 | 11785篇 |
1989年 | 11573篇 |
1988年 | 10996篇 |
1987年 | 10313篇 |
1986年 | 9777篇 |
1985年 | 8756篇 |
1984年 | 6735篇 |
1983年 | 6682篇 |
1982年 | 7686篇 |
1981年 | 7233篇 |
1980年 | 6858篇 |
1979年 | 6733篇 |
1978年 | 5861篇 |
1977年 | 6149篇 |
1976年 | 5772篇 |
1975年 | 5511篇 |
1974年 | 5070篇 |
1972年 | 4792篇 |
排序方式: 共有10000条查询结果,搜索用时 562 毫秒
51.
52.
目的 探讨PDCA 循环在消化道肿瘤伴糖尿病患者营养全程管理中的效果观察。方法 运用PDCA循环对80例不同程度营养不良的消化道肿瘤伴糖尿病患者实施营养全程管理,比较干预前后患者的体重、BMI指数、糖化血红蛋白、血红蛋白、总蛋白、白蛋白及球蛋白水平。结果 患者血红蛋白、总蛋白、白蛋白及球蛋白水平均有提高,比较差异均有统计学意义(P<0.05)。结论 PDCA循环管理在消化道肿瘤伴糖尿病患者营养全程管理中有较大的优势, 值得推广。 相似文献
53.
54.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
55.
目的分析成人血液系统恶性肿瘤患者接受强烈化疗后中性粒细胞减少性肠炎(NE)的发生率、危险因素及预后情况。方法收集2004至2013年接受化疗的1804例血液系统恶性肿瘤患者,记录患者血常规、凝血检测和血液生化检测结果,并记录患者年龄、性别、原发病、既往化疗次数、既往化疗方案中是否使用阿糖胞苷、临床症状、肠壁厚度、中性粒细胞最低计数、中性粒细胞缺乏持续时间、NE的治疗方法和预后等,探讨NE起病诱因、临床特征、腹部B超特点、症状的预后意义及化疗药物对发病的影响等。结果1804例患者中226例(12.5%)化疗后合并NE,化疗后10~19d起病,中位起病时间为化疗后第14天。发生NE后26例患者死亡,病死率11.5%。化疗药物包括阿糖胞苷、临床症状≥4项、中性粒细胞缺乏持续超过7d以及B超下肠壁厚度≥10mm的患者病死率相对较高。结论NE是接受强烈化疗的血液系统肿瘤患者的严重的并发症,发生NE后患者病死率较高。 相似文献
56.
Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), VerifyNow? aspirin system and thromboelastography (TEG), for monitoring the short-term aspirin responses in healthy individuals. Ten healthy young men took 100?mg/d aspirin for 3-day treatment. Platelet function was measured via PL-11, LTA, VerifyNow and TEG, respectively. The blood samples were collected at baseline, 2 hour, 1 day during the aspirin treatment and 1 day, 5?±?1 days, 8?±?1 days after the aspirin withdrawal. Moreover, 90 additional healthy subjects were recruited to establish a reference range for PL-11. Platelet function of healthy subjects decreased significantly 2 hours after 100?mg/d aspirin intake and began to recover during 4–6 days after the aspirin withdrawal. Correlations between methods were PL-11 vs. LTA (r?=?0.614, p?<?0.01); PL-11 vs. VerifyNow (r?=?0.829, p?<?0.01); PL-11 vs. TEG (r?=?0.697, p?<?0.001). There was no significant bias between PL-11 and LTA at baseline (bias?=?1.94%, p?=?0.804) using Bland-Altman analysis, while the data of PL-11 were significantly higher than LTA (bias?=?24.02%, p?<?0.001) during the aspirin therapy. The reference range for PL-11 in healthy young individuals was from 66.8 to 90.5% (95%CI). When aspirin low-responsiveness was defined as LTA?>?20%, the cut-off values for each method were, respectively: PL-11?>?50%, VerifyNow?>?533 ARU, TEG?>?60.2%. The results of different platelet function assays were uninterchangeable for monitoring aspirin response and correlations among them were also varied. Correlations among PL-11 and other three major assays suggested the ability of PL-11 to assess the treatment effects of aspirin. But a large cohort study is needed to confirm the cut-off value of aspirin response detected by PL-11. 相似文献
57.
Context The root of Helicteres angustifolia L. (Sterculiaceae) has been used as folk herbal drug to treat cancer, bacterial infections, inflammatory, and flu in China. However, there is no report on its antidiabetic activity.Objective This study evaluates the antidiabetic activity of ethanol extract from H. angustifolia root.Materials and methods The promoting effect of H. angustifolia root ethanol extract (25, 50, and 100 μg/mL) on glucose uptake was evaluated using HepG2 cell, differentiated C2C12 myotubes, and differentiated 3T3-L1 adipocytes. The antidiabetic activity of the extract was assessed in vivo using STZ-induced diabetic rats by orally administration of the extract (200 and 400?mg/kg b.w.) once per day for 28 d. Blood glucose, TG, TC, TP, HDL-C, UA, BUN, AST, ALT, insulin, and HOMA-IR were analyzed.Results The results showed that the extract increased glucose uptake in C2C12 myotubes and 3T3-L1 adipocytes with an IC50 value of 79.95 and 135.96 μg/mL, respectively. And about 12%, 19%, and 10% (p < 0.05) in HepG2 cells when compared with the control at the concentration of 25, 50, and 100 μg/mL, respectively. After 28 days’ treatment with the extract, significant reduction was observed in blood glucose, HOMA-IR, TC, TG, UA, BUN, AST, and ALT levels, while the levels of TP and HDL cholesterol increased.Discussion and conclusion These results suggest that H. angustifolia root ethanol extract possess potent antidiabetic activity, which is the first report on antidiabetic activity of this plant. 相似文献
58.
59.
骨碎补是历代临床常用中药,具有疗伤止痛、补肾强骨、消风祛斑等功效。其主要含黄酮、苯丙素、三萜、酚酸及其苷等类化学成分,现代研究表明骨碎补具有抗骨质疏松、促进骨折愈合、促软骨再生、护牙健齿、保护肾功能、抗炎、防治中毒性耳聋、降血脂等多种生物活性,开发前景广阔。本文对近年来骨碎补的化学成分、药理作用及临床应用研究进行综述,以期为骨碎补的进一步深入系统的研究和开发利用提供依据。 相似文献
60.